The Utility of Observational Studies in Clinical Decision Making: Lessons Learned from Statin Trials

References

• . Grundy SM, Cleeman JI, Merz CN, ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–732
   PubMedGoogle Scholar
• . Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519
   PubMed Web of Science ®Google Scholar
• . von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457
   PubMed Web of Science ®Google Scholar
• . Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191–1194
   PubMed Web of Science ®Google Scholar
• . Keys A, Aravanis C, Blackburn HW, . Epidemiological studies related to coronary heart disease: characteristics of men aged 40–59 in seven countries. Acta Med Scand Suppl. 1966;460:1–392
   PubMedGoogle Scholar
• . Menotti A, Lanti M, Kromhout D, . Homogeneity in the relationship of serum cholesterol to coronary deaths across different cultures: 40-year follow-up of the Seven Countries Study. Eur J Cardiovasc Prev Rehabil. 2008;15(6):719–725
   PubMedGoogle Scholar
• . Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279–281
   PubMed Web of Science ®Google Scholar
• . Ingelsson E, Schaefer EJ, Contois JH, . Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298(7):776–785
   PubMed Web of Science ®Google Scholar
• . LaRosa JC, Grundy SM, Waters DD, . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435
   PubMed Web of Science ®Google Scholar
• . Colhoun HM, Betteridge DJ, Durrington PN, ; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696
   PubMed Web of Science ®Google Scholar
• . Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22
   PubMed Web of Science ®Google Scholar
• . Shepherd J, Cobbe SM, Ford I, . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–1307
   PubMed Web of Science ®Google Scholar
• . Downs JR, Clearfield M, Weis S, . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–1622
   PubMed Web of Science ®Google Scholar
• . Brown WV, Bays HE, Hassman DR, . Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J. 2002;144(6):1036–1043
   PubMed Web of Science ®Google Scholar
• . LaRosa JC, Grundy SM, Waters DD, ; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435
   PubMed Web of Science ®Google Scholar
• . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389
   PubMed Web of Science ®Google Scholar
• . Stender S, Schuster H, Barter P, Watkins C, Kallend D. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005;7(4):430–438
   PubMed Web of Science ®Google Scholar
• . Insull W Jr, Ghali JK, Hassman DR, Yas JW, Gandhi SK, Miller E; SOLAR Study Group.Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc. 2007;82(5):543–550
   PubMed Web of Science ®Google Scholar
• . Hounslow N, Budinski D. Pitavastatin is non-inferior to simvastatin and atorvastatin at usual therapeutic doses in primary hypercholesterolemia or combined dyslipidemia and shows sustained efficacy during 52 weeks treatment. Eur Heart J. 2009;30:764
   Web of Science ®Google Scholar
• . Graham I, Atar D, Borch-Johnsen K, ; ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis. 2007;194(1):1–45
   PubMed Web of Science ®Google Scholar
• . Yokote K, Bujo H, Hanaoka H, . Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201(2):345–352
   PubMed Web of Science ®Google Scholar
• . Lee SH, Chung N, Kwan J, . Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007;29(11):2365–2373
   PubMed Web of Science ®Google Scholar
• . Pedersen TR, Faergeman O, Kastelein JJ, . High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445
   PubMed Web of Science ®Google Scholar
• . Isaacsohn JL, Davidson MH, Hunninghake D, Singer R, McLain R, Black DM. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000;86(2):250–252
   PubMed Web of Science ®Google Scholar
• . Koren MJ, Hunninghake DB; ALLIANCE Investigators.Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol. 2004;44(9):1772–1779
   PubMed Web of Science ®Google Scholar
• . Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther. 2008;30(1):195–205
   PubMed Web of Science ®Google Scholar
• . Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clin Proc. 2008;83(12):1316–1325
   PubMed Web of Science ®Google Scholar
• . Simpson RJ Jr, Signorovitch J, Birnbaum H, . Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clin Proc. 2009;84(12):1065–1072
   PubMed Web of Science ®Google Scholar
• . Dieleman JP, van Wyk JT, van Wijk MA, . Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin. 2005;21(9):1461–1468
   PubMed Web of Science ®Google Scholar
• . Choudhry NK, Levin R, Winkelmayer WC. Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart. 2007;93(8):945–951
   PubMed Web of Science ®Google Scholar
• . Cannon CP, Braunwald E, McCabe CH, . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504
   PubMed Web of Science ®Google Scholar
• . Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ. 2009;338:b81
   PubMed Web of Science ®Google Scholar
• . Link E, Parish S, Armitage J, . SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008;359(8):789–799
   PubMed Web of Science ®Google Scholar
• . Hess G, Sanders KN, Hill J, Liu LZ. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care. 2007;13( suppl 3):S80–S85
   PubMed Web of Science ®Google Scholar
• . Butler R, Wainwright J. Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet. 2007;369(9555):27
   PubMed Web of Science ®Google Scholar
• . Phillips B, Roberts C, Rudolph AE, Morant S, Aziz F, O'Regan C. Switching statins: the impact on patient outcomes. B J Cardiol. 2007;14:280–285
   Google Scholar
• . Laurie SJ. NICE on lipid modification: NICE's simplified approach to lipids will not work. BMJ. 2008;336(7657):1324
   PubMed Web of Science ®Google Scholar